SINGLE-AGENT IBRUTINIB IN RITUXIMAB-REFRACTORY PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA (WM): UPDATED RESULTS FROM A MULTICENTER, OPEN-LABEL PHASE 3 SUBSTUDY (INNOVATETM)

被引：0

作者：

Dimopoulos, M. ^{[1
]}

Trotman, J. ^{[2
]}

Tedeschi, A. ^{[3
]}

Matous, J. V. ^{[4
]}

Macdonald, D. ^{[5
]}

Tam, C. ^{[6
,7
]}

Tournilhac, O. ^{[8
]}

Ma, S. ^{[9
]}

Oriol, A. ^{[10
]}

Heffner, L. ^{[11
]}

Shustik, C. ^{[12
]}

Garcia-Sanz, R. ^{[13
]}

Cornell, R. F. ^{[14
]}

Fernandez de Larrea, C. ^{[15
]}

Castillo, J. J. ^{[16
]}

Granell, M. ^{[17
]}

Kyrtsonis, M. C. ^{[18
]}

Leblond, V. ^{[17
,19
]}

Symeonidis, A. ^{[20
]}

Singh, P. ^{[21
]}

Li, J. ^{[21
]}

Graef, T. ^{[21
]}

Bilotti, E. ^{[21
]}

Treon, S. ^{[16
]}

Buske, C. ^{[22
]}

机构：

[1] Univ Athens, Sch Med, Athens 11528, Greece

[2] Univ Sydney, Concord Hosp, Sydney, NSW 2006, Australia

[3] Osped Niguarda Ca Granda, Milan, Italy

[4] Colorado Blood Canc Inst, Denver, CO USA

[5] Dalhousie Univ, Halifax, NS, Canada

[6] Peter MacCallum Canc Ctr, Melbourne, Australia

[7] St Vincents Hosp, Melbourne, Australia

[8] CHU Clermont Ferrand, Hematol Clin Adulte & Therapie Cellulaire, Clermont Ferrand, France

[9] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA

[10] Hosp Badalona Germans Trias & Pujol, Catala Oncol 9Inst, Barcelona, Spain

[11] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[12] McGill Univ Hlth Ctr, Royal Victoria Hosp, Montreal, PQ, Canada

[13] Hosp Univ Salamanca, Salamanca, Spain

[14] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[15] IDIBAPS, Hosp Clin Barcelona, Barcelona, Spain

[16] Dana Farber Canc Inst, Boston, MA 02115 USA

[17] Hosp Sant Pau, Barcelona, Spain

[18] Univ Athens, Athens 11528, Greece

[19] UPMC Univ Paris, Hop Pitie Salpetriere APHP, Paris, France

[20] Univ Patras, Medial Sch, Patras, Greece

[21] AbbVie Co, Pharmacyclics LLC, Sunnyvale, CA USA

[22] Univ Hosp Ulm, Inst Expt Canc Res, Comprehens Canc Ctr Ulm, INNOVATE TM Study Grp, Ulm, Germany

来源：

HAEMATOLOGICA | 2016年 / 101卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P652

引用

页码：256 / 257

页数：2

共 50 条

[31] UPDATED RESULTS FROM A MULTICENTER, OPEN-LABEL, DOSE-ESCALATION PHASE 1B/2 STUDY OF SINGLE-AGENT OPROZOMIB (OPZ) IN PATIENTS (PTS) WITH HEMATOLOGIC MALIGNANCIES, INCLUDING MULTIPLE MYELOMA (MM)
Vij, R.
Savona, M.
Siegel, D.
Kaufman, J. L.
Badros, A.
Ghobrial, I.
Paner, A.
Jagannath, S.
Jakubowiak, A.
Mikhael, J.
Kapoor, P.
Neuman, L.
Obreja, M.
Berdeja, J.
HAEMATOLOGICA, 2015, 100 : 251 - 251
[32] A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenstrom's macroglobulinemia (vol 111, pg 3327, 2020)
Sekiguchi, Naohiro
Rai, Shinya
Munakata, Wataru
Suzuki, Kenshi
Handa, Hiroshi
Shibayama, Hirohiko
Endo, Tomoyuki
Terui, Yasuhito
Iwaki, Noriko
Fukuhara, Noriko
Tatetsu, Hiro
Iida, Shinsuke
Ishikawa, Takayuki
Shiibashi, Ryota
Izutsu, Koji
CANCER SCIENCE, 2021, 112 (04) : 1669 - 1669
[33] A phase II open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation.
Shapira-Frommer, Ronnie
Oza, Amit M.
Domchek, Susan M.
Balmana, Judith
Patel, Manish R.
Chen, Lee-may
Drew, Yvette
Burris, Howard A.
Korach, Jacob
Flynn, Michael
Bowering, Valerie Lydia
Morgan, Mark Aloysuis
Watkins, Simon Paul
Simpson, Dayna
Goble, Sandra
Maloney, Lara
Kristeleit, Rebecca Sophie
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[34] Ibrutinib Combined with Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Arm 1+Arm 2 Results from a Multicenter, Open-Label Phase 2 Study
Fowler, Nathan
Nastoupil, Loretta
de Vos, Sven
Knapp, Mark
Flinn, Ian W.
Chen, Robert W.
Advani, Ranjana H.
Bhatia, Sumeet
Martin, Peter
Mena, Raul
Suzuki, Samuel
Beaupre, Darrin M.
Neuenburg, Jutta K.
Palomba, M. Lia
BLOOD, 2016, 128 (22)
[35] UPDATED RESULTS FROM ASPIRE AND ENDEAVOR, RANDOMISED, OPEN-LABEL, MULTICENTRE PHASE 3 STUDIES OF CARFILZOMIB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Siegel, D.
Oriol, A.
Rajnics, P.
Minarik, J.
Hungria, V.
Lee, J. H.
Song, K.
Obreja, M.
Aggarwal, S.
Hajek, R.
HAEMATOLOGICA, 2017, 102 : 108 - 108
[36] Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma
Venkatesh, H
Di Bella, N
Flynn, TP
Vellek, MJ
Boehm, KA
Asmar, L
CLINICAL LYMPHOMA, 2004, 5 (02): : 110 - 115
[37] Ibrutinib Vs Temsirolimus: Results from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle Cell Lymphoma (MCL)
Rule, Simon
Jurczak, Wojciech
Jerkeman, Mats
Santucci, Rodrigo
Rusconi, Chiara
Trneny, Marek
Offner, Fritz
Caballero, Dolores
Joao, Cristina
Witzens-Harig, Mathias
Hess, Georg
Bence-Bruckler, Isabelle
Cho, Seok-Goo
Balasubramanian, Sriram
Bandyopadhyay, Nibedita
Sun, Steven
Goldberg, Jenna
Bothos, John
Traina, Shana
Enny, Christopher
Rizo, Aleksandra
Vermeulen, Jessica
Dreyling, Martin H.
BLOOD, 2015, 126 (23)
[38] Phase 1, multicenter, open-label study of single-agent bispecific antibody T-cell engager GBR 1342 in relapsed/refractory multiple myeloma.
Richter, Joshua Ryan
Wermke, Martin
Kauh, John S.
Back, Jonathan
Salhi, Yacine
Reddy, Venkateshwar
Bayever, Eliel
Landgren, Carl Ola
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
[39] Phase 1, multicenter, open-label study of single-agent bispecific antibody t-cell engager GBR 1342 in relapsed/refractory multiple myeloma.
Richter, Joshua Ryan
Landgren, Carl Ola
Kauh, John S.
Back, Jonathan
Salhi, Yacine
Reddy, Venkateshwar
Bayever, Eliel
Berdeja, Jesus G.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[40] Efficacy and safety of single-agent lenalidomide for relapsed/refractory mantle cell lymphoma (MCL): Preliminary results from a UK-based open-label phase II trial
Eve, H. E.
Bullard, S. H.
Rule, S. A. J.
BRITISH JOURNAL OF HAEMATOLOGY, 2010, 149 : 42 - 43

← 1 2 3 4 5 →